Company Intelligence
Tempus
MedTwenty Company Score 87Diagnostics · AI · Chicago, United States · Founded 2015
Sequencing-led precision medicine company combining clinical genomic profiling with a large real-world oncology data asset. Now the acquirer of Personalis and a direct competitor to Foundation Medicine in comprehensive genomic profiling.
Key facts
Employees2,400
Revenue$693m (FY2025)
Valuation$8.1bn
Last roundIPO, June 2024
Funding history
| Date | Round | Amount | Lead investor |
|---|---|---|---|
| Jun 2024 | IPO | $410m | Public markets |
| Oct 2022 | Series G | $275m |
Acquisitions
Sep 2026 · Personalis$1.5bn
Feb 2024 · ArterysUndisclosed
Timeline
- 26 Sep 2026Agrees to acquire Personalis for $1.5bn.
- 12 Jun 2024Lists on Nasdaq, raising $410m.
- 3 Mar 2023Enters oncology genomics collaboration with Personalis.
Benchmarks, competitor comparison and export
Professional membership unlocks side-by-side competitor comparison, historical financial series and CSV export for this company.
Upgrade